|
|
|
| Advancing Retinal Gene Therapy with Atsena Therapeutics' Dr. Kenji Fujita | On Cell & Gene: The Podcast, Erin Harris chats with Dr. Kenji Fujita, CMO of Atsena Therapeutics, about groundbreaking retinal gene therapy for X-linked retinoschisis (XLRS)—a rare genetic disease with no FDA-approved treatment. Discover how Atsena’s AAV vector technology aims to overcome gene delivery challenges and what the recent Fast Track designation means for patients. Listen now and subscribe so you never miss an episode. |
|
|
|
|
A looming patent cliff is driving Big Pharma reorganization. Executives making career moves must understand differences in Big Pharma and biotech culture and expectations to be successful. |
|
|
|
|
|
|
|
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|